Ocumetics Lens shows early vision gains in trials

Executive Summary

• Ocumetics Technology Corp. released one-month postoperative results for all patients in Group 1 of its first-in-human clinical study evaluating the Ocumetics Accommodating Intraocular Lens.
• The results demonstrate that Corrected Distance Visual Acuity (CDVA) ranged from 20/32 to 20/25, with outcomes meeting or exceeding internal expectations for this early stage of recovery.
• The company confirmed the safety of the implantation and surgical technique, and announced that planning for Group 2 surgeries is underway with updates expected in the coming weeks.

Key Details

• Study Phase: First-in-human early feasibility study for the Ocumetics Accommodating Intraocular Lens.
• Patient Group: Group 1 (Day 1 and Day 2 surgeries).
• Surgery Timeline: Group 1 surgeries completed in August 2025 (Day 1) and September 2025 (Day 2).
• One-Month Postoperative Results:
  • All Group 1 patients completed one-month postoperative exams.
  • Corrected Distance Visual Acuity (CDVA) ranged from 20/32 to 20/25.
  • Patients began the study with significantly impaired distance vision due to cataracts.
• Primary Objectives Met:
  • Confirmed safety of the lens.
  • Evaluated and confirmed surgical technique.
  • Assessed distance vision restoration.
• Product Description: The intraocular lens fits within the natural lens compartment, designed to allow the eye's natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses.
• Next Steps: Planning for Group 2 surgeries is underway; updates to follow in the coming weeks.

Notable Quotes

• Dean Burns, President and CEO: "We are thrilled by the visual outcomes we're seeing in our first group of patients... These results have met, and in some cases, exceeded internal expectations at this early stage of recovery. Every Group 1 patient is showing steady improvement with visual acuity. These results strongly reinforce our belief in the transformative potential of the Ocumetics Lens."
• Dr. Doyle Stulting, Chief Medical Officer: "Achieving 20/32 or better vision this soon after surgery is remarkable. These data highlight the excellent optical quality and stability of the Ocumetics Lens and give us great confidence as we advance to the next patient groups."